fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-09-08
Biotech partner: Galapagos (Belgium)
Pharma Partner: GSK (UK)
Type of agreement: * R&D
* other
Compound: GSK research centre in Zagreb This center was GSK's Macrolide Center of Excellence for Drug Discovery
Nature of the agreement: Galapagos and GSK have reached an agreement for Galapagos to acquire GSK's state-of-the art research centre in Zagreb, Croatia. Terms of the deal include the acquisition of the research centre along with the transfer of approximately 130 staff. In addition,
The Zagreb centre has a strong heritage in the area of antibacterial research having served as GSK's Macrolide Center of Excellence for Drug Discovery and before that as an R&D site for Pliva, the independent pharmaceutical company and founder of the blockbuster antibiotic azithromycin.
The integrated capabilities in the operations will allow Galapagos to resource research programmes from molecule through to the clinic in alignment with its milestone-driven alliance model. The site will form the basis of a newly created third Galapagos business unit, Internal Outsourcing, that will provide flexible, additional capacity for the Galapagos Group.
GSK's senior researcher from the Zagreb site, Dr. Radan Spaventi, will join the Galapagos Executive Team as Senior Vice President.
Financial terms of the agreement: Galapagos will provide R&D services to GSK under a three year fee-for-service contract to the value of €14 M.
Further terms were not disclosed.

Go back to previous page